接受辅助抗PD1治疗的已切除III/IV期黑色素瘤患者的真实世界健康相关生活质量结局
本研究利用澳大利亚和荷兰两个黑色素瘤登记处的数据,纳入92例接受辅助抗PD1治疗且完成基线与至少一次基线后HRQOL评估的已切除III/IV期黑色素瘤患者,采用EORTC QLQ-C30在基线、3、6、12个月评估HRQOL。结果显示平均症状和功能评分在12个月时改善或保持稳定,但相当比例患者角色(39%)、社交(41%)和情绪(50%)功能出现临床显著下降;年轻患者更易出现角色(OR=1.07,95%CI:1.02-1.13,p<0.01)和社交(OR=1.06,95%CI:1.01-1.11,p=0.013)功能临床显著恶化。
要点
- 辅助抗PD1治疗12个月时,39%患者角色功能、41%社交功能、50%情绪功能出现临床显著下降。
- 年轻患者角色功能恶化OR=1.07(95%CI:1.02-1.13,p<0.01),社交功能恶化OR=1.06(95%CI:1.01-1.11,p=0.013)。
- 平均症状和功能评分在12个月时较基线改善或保持稳定。
核心结论
- 相当比例接受辅助抗PD1治疗的已切除III/IV期黑色素瘤患者在12个月时角色、社交和情绪功能出现临床显著下降,提示辅助抗PD1治疗期间可能出现需支持治疗干预的HRQOL问题。
研究设计与样本
- 研究使用澳大利亚和荷兰两个黑色素瘤登记处的数据,纳入接受辅助抗PD1治疗且完成基线和至少一次基线后HRQOL评估的已切除III/IV期黑色素瘤患者,共92例。
- HRQOL采用EORTC QLQ-C30在基线、3、6和12个月进行评估,并使用既定阈值解读QLQ-C30评分变化。
主要发现
- 92例患者中,平均症状和功能评分在12个月时较基线改善或保持稳定。
- 12个月时较基线,39%患者角色功能(μ=-50.8)、41%社交功能(μ=-32.7)、50%情绪功能(μ=-25.1)出现临床显著下降。
- 年轻患者更易出现角色功能临床显著恶化(OR=1.07,95%CI:1.02-1.13,p<0.01)和社交功能临床显著恶化(OR=1.06,95%CI:1.01-1.11,p=0.013)。
临床怎么用
- 作者指出,辅助抗PD1治疗期间可能出现需支持治疗干预的HRQOL问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While adjuvant therapy with anti-programmed cell death protein-1 (anti-PD1) for patients with resected stage III/IV melanoma has been shown to improve recurrence-free survival, the overall survival benefit remains uncertain. This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma METHODS: Data was used from two melanoma registries in Australia and the Netherlands. Patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 who completed a baseline and at least one post-baseline HRQOL assessment were included. HRQOL was assessed using the EORTC QLQ-C30 at baseline, 3, 6, and 12 months. Established thresholds were used for interpreting changes in QLQ-C30 scores. RESULTS: 92 patients were included. Mean symptom and functioning scores improved or remained stable at 12 months compared to baseline. However, a substantial proportion of patients experienced a clinically significant decline in role (39%, μ = -50.8), social (41%, μ = -32.7), or emotional (50%, μ = -25.1) functioning at 12 months compared to baseline. Younger patients were more likely to experience clinically significant deteriorations in role (OR=1.07, 95% CI: 1.02-1.13, p < 0.01) and social (OR=1.06, 95% CI: 1.01-1.11, p = 0.013) functioning. CONCLUSION: A significant proportion of patients with resected stage III/IV melanoma who received adjuvant anti-PD1 experienced clinically significant declines in role, social and emotional functioning at 12 months compared to baseline. This highlights the HRQOL issues that may arise during adjuvant anti-PD1 therapy which may require supportive care intervention.
引用
- Egeler M, Lai-Kwon J, Tissier R, et al. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy. Eur J Cancer. 2024. PMID: 38340383. doi:10.1016/j.ejca.2024.113601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。